Understanding Triple-Negative Breast Cancer

摘要: It is estimated that over 200,000 new cases of invasive breast cancer will be diagnosed in the United States 2012 and approximately 40,000 women die from their disease. Triple-negative (TNBC), which lacks expression estrogen receptor (ER) progesterone (PR), does not overexpress human epidermal growth factor receptor-2 (HER-2) represents 15 % all cancers often associated with a more aggressive underlying biology. Patients TNBC experience rapid disease progression poorer disease-related overall survival first few years after diagnosis comparison to hormone-receptor positive counterparts. Furthermore, this subset has limited therapeutic options aside traditional cytotoxic chemotherapy agents as they do benefit generally well-tolerated endocrine-targeted therapies anti-HER2 drugs. In chapter we review epidemiology, risk factors, prognosis varied molecular clinicopathologic features characterize TNBC. addition summarizes available data for use treatment explores ongoing development targeted subgroup cancers.